BioSpace News Archive

Endologix® Inc., a developer and marketer of innovative treatments for aortic disorders, announced that it has completed enrollment in the EVAS2 Confirmatory Clinical Study to Evaluate the Nellix EndoVascular Aneurysm Sealing System.

Pulse Biosciences, Inc., a novel bioelectric medicine company, announced financial results for the first quarter ended March 31, 2020.

Endologix, Inc., a developer and marketer of innovative treatments for aortic disorders, announced its financial results for the first quarter ended March 31, 2020.

Omeros Corporation announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2020, which include:

Kodiak Sciences Inc., a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, announced that management will present at the virtual Bank of America Merrill Lynch Health Care Conference on Wednesday, May 13, 2020 at 11:20 a.m. Pacific Time.

STRO-002 Encouraging Interim Phase 1 Clinical Data from an Ongoing Dose Escalation Study in Ovarian Cancer Presented at the AACR Virtual Meeting

Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today provided a corporate update and reported financial results for the first quarter ended March 31, 2020.

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today reported financial results for the first quarter ended March 31, 2020 and provided a corporate update.

AdaptHealth Corp., a leading provider of home healthcare equipment, medical supplies to the home and related services in the United States, announced that management will present at the following virtual healthcare conferences in May:

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), today reported financial results for the first quarter of 2020.